Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIO to redefine expectations for treatment of children ophilia A Paris, March 2, 2023. The XTEND-Kids phase
/PRNewswire/ Sobi® today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant),.
FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection Paris and Stockholm – February 23, 2023 – The U.S. Food and Drug Administration (FDA) has approved ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-V.
Investegate announcements from Sanofi - Aventis Groupe, Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection